Shaping the focus of myopia control

At Myoptechs, our vision is to help kids with myopia see clearly, while helping protect their eyes for life. Our patented technology is being developed in both contact lenses and glasses, providing comprehensive vision correction to help slow the progression of myopia while providing exceptionally clear vision.

Find Out How

6 yo

Myopia starts developing as early as 6 years old ^[2]

28 %

of the world’s population has myopia ^[2]

5 B

people, or 50% of the world, will have myopia by 2050 ^[2]

75 %

Prevalence in Eastern Asia is already over 75% ^[3]

ABOUT MYOPIA

A prevalent disease with major implications

Often called nearsightedness, myopia is a chronic, progressive eye disease that starts early in life and is characterized by worsening distance vision and excessive eye elongation. Any degree of myopia increases the risk of sight-threatening complications, including cataracts, glaucoma, retinal detachment, and myopic macular degeneration, with certain complications leading to blindness in adulthood^[1].

The mission of Myoptechs is to help reduce the short- and long-term vision implications of the disease.

Learn More

THE OPPORTUNITY

Controlling the progression of myopia early is critical

Myopia typically develops in childhood and often stops progressing by age 20^[4], making early treatment essential. While traditional solutions only correct distance vision, the new category of myopia control optical correction improves distance vision while addressing the root problem — excessive eye elongation.

Clinical studies show that multifocal optics, which add power in the periphery and generate myopic defocus, help slow eye growth. Early intervention with these advanced solutions can reduce long-term risks and lead to better lifelong eye health.

So, what does this mean for you?

With this paradigm shift toward more effective solutions, there is an opportunity to help billions of people worldwide, which translates to a meaningful opportunity for the eyecare industry, with a predicted $20 billion Total Addressable Market for myopia control optical correction^[5].

By developing both contact lenses and glasses, we’re providing options to kids that can be tailored to their lifestyle and prescription needs. It also allows us to serve over 75 percent of the myopia control optical correction market.

PARTNER WITH US

OUR TECHNOLOGY

Breakthrough patented technology

Myoptechs’s Faceted Optical System™ is being designed to maximize an optical signal beneficial for slowing myopia progress as compared to early-generation technologies for myopia control.

The Myoptechs difference

Comprehensive vision correction

We’re one of the only companies designing both myopia control glasses and contact lenses. That means kids can easily transition between glasses and contacts as they grow and their needs change.

Patented design

Our Faceted Optical System™ is designed specifically for myopia vs. early-generation technologies that incorporate older multifocal optical design principles.

Designed for results

Designed to provide exceptionally clear vision while maximizing myopic defocus, an optical signal beneficial for slowing myopia progression.

Maximizes myopic defocus

Retinal imaging simulations, using scientifically validated methodology, show 3X the myopic defocus with the Myoptechs optical design vs. a multifocal contact lens indicated to slow myopia progression.

Comprehensive vision correction

We’re one of the only companies designing both myopia control glasses and contact lenses. That means kids can easily transition between glasses and contacts as they grow and their needs change.

Patented design

Our Faceted Optical System™ is designed specifically for myopia vs. early-generation technologies that incorporate older multifocal optical design principles.

Designed for results

Designed to provide exceptionally clear vision while maximizing myopic defocus, an optical signal beneficial for slowing myopia progression.

Maximizes myopic defocus

Retinal imaging simulations, using scientifically validated methodology, show 3X the myopic defocus with the Myoptechs optical design vs. a multifocal contact lens indicated to slow myopia progression.

These statements have not been evaluated by the FDA and the device is not currently available for purchase or use in the United States.

Our Momentum

From concept to clinically validated

Technology licensed
Secured the exclusive worldwide license from The Ohio State Innovation Foundation.

Patent awarded
Strengthened our IP position with a granted US patent and filed applications worldwide (12,210,227 B2).

Manufacturability proven
Successfully developed and proved manufacturability for both glasses and contacts.

Clinically validated
In three clinical studies, the Myoptechs contact lens showed excellent visual acuity, optimal fitting characteristics, and dependable comfort, with no safety-related concerns.